+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating treatments for people diagnosed with Stage I HER2-positive invasive breast cancer. This study compares two combinations of HER2-targeted therapies given after surgery to see how well they work and their side effects. The study focuses on whether trastuzumab-emtansine followed by subcutaneous trastuzumab has fewer side effects than the standard treatment of paclitaxel plus trastuzumab. It also aims to learn about long-term benefits and disease-free survival. Participants will be randomly assigned to one of two treatment groups. One group receives intravenous trastuzumab-emtansine every 3 weeks for 18 weeks, followed by subcutaneous trastuzumab every 3 weeks for 33 weeks. The other group receives weekly intravenous paclitaxel for 12 weeks along with subcutaneous trastuzumab every 3 weeks for 51 weeks the first four doses of trastuzumab are given with paclitaxel. Treatments are given over a total of one year. During the study, participants will undergo screening, laboratory tests, and follow-up visits. Researchers will monitor side effects and measure disease-free survival for up to 72 months after randomization. Quality of life, symptoms, work productivity, cardiac function, and gene profiling will also be evaluated. Participants will be followed for five years after completing treatment to collect long-term data.

Age: 18Years +All GendersPhase 2
53 locations
O

Actively Recruiting

Researchers are evaluating the long-term safety and effectiveness of CCM therapy in treating heart failure in a real-world setting. This global, observational study includes both prospective and retrospective patients who have received or will receive CCM therapy using Impulse Dynamics systems, including future technologies such as CCM-D. Participants will be followed for at least 5 years to gather comprehensive data. Participants receive CCM therapy through an Impulse Dynamics device as part of their regular care. The study does not assign treatments but observes patients who have been implanted or will be implanted with these devices. The registry collects data from multiple centers worldwide, tracking outcomes over time without altering the standard treatment process. During the study, participants will be monitored regularly to assess hospitalizations related to heart failure, device- or procedure-related complications, mortality, functional capacity, and quality of life among other measures. Assessments include questionnaires like the Kansas City Cardiomyopathy Questionnaire and evaluations of clinical outcomes, device compliance, and cardiovascular changes. Follow-up will last for at least five years, ensuring long-term safety and effectiveness data collection.

Age: 18Years +All Genders
30 locations
C

Actively Recruiting

Researchers are investigating whether combining chemotherapy with the immunotherapy drug pembrolizumab improves overall survival compared to pembrolizumab alone in older adults aged 70 and above with advanced stage IIIB-IV non-small cell lung cancer. This phase III trial focuses on a vulnerable population and aims to evaluate survival, disease progression, treatment response, toxicity, quality of life, and other health factors. The study also explores how gut microbes and geriatric assessments relate to treatment outcomes. Participants are randomly assigned to one of two groups. In the first group, patients receive pembrolizumab intravenously every 21 days for four cycles, followed by maintenance doses every 21 or 42 days for up to two years if there is no disease progression or severe side effects. In the second group, patients receive pembrolizumab plus a chemotherapy regimen chosen by the investigator, given intravenously on specific schedules for four cycles, followed by the same pembrolizumab maintenance as the first group. Imaging tests like MRI, CT, and PET scans are done at the start and throughout treatment. During the study, participants undergo regular clinical assessments, imaging, and laboratory tests to monitor their cancer and overall health. Follow-up visits occur every three months for up to two years and then every six months until five years after starting treatment. Researchers measure overall survival, progression-free survival, response rates, side effects, and quality of life. The study also collects patient-reported information and evaluates safety and tolerability over time.

Age: 70Years +All GendersPhase 3
329 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
C

Actively Recruiting

Researchers are comparing two chemotherapy regimens, mFOLFIRINOX and mFOLFOX, both with or without the immunotherapy drug nivolumab, for treating patients with advanced, unresectable, or metastatic HER2-negative adenocarcinoma of the esophagus, gastroesophageal junction, or stomach. This phase III trial aims to see if mFOLFIRINOX with or without nivolumab improves overall survival compared to mFOLFOX with or without nivolumab. The study also evaluates treatment safety, response rates, and explores biomarkers like PD-L1 combined positive score and cell-free DNA. Participants randomized to one of two groups will receive intravenous chemotherapy every 14 days in cycles up to 12 times. One group receives fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan, with nivolumab given as clinically indicated. The other group receives fluorouracil, leucovorin calcium, and oxaliplatin, also with nivolumab as needed. Throughout the study, patients undergo MRI and CT scans and may have blood samples collected. Nivolumab administration depends on clinical need. During the trial, participants will have regular imaging to monitor tumor status and blood tests to track biomarkers. Patient-reported outcomes on treatment side effects are collected at baseline and during cycles. After treatment, participants are followed every six months for up to three years or until tumor progression or withdrawal. The main outcome measured is overall survival over two years, with additional assessments of progression-free survival, response duration, and safety up to three years.

Age: 18Years +All GendersPhase 3
802 locations
C

Actively Recruiting

Researchers are evaluating whether simply observing patients after surgery is as effective as continuing pembrolizumab treatment in preventing cancer recurrence in people with early-stage triple-negative breast cancer TNBC who had a complete response after receiving chemotherapy plus pembrolizumab before surgery. This Phase III trial aims to determine if stopping pembrolizumab post-surgery can maintain recurrence-free survival while potentially improving quality of life and reducing treatment burden. Participants are randomly assigned to one of two groups after finishing chemotherapy with pembrolizumab and surgery. One group continues pembrolizumab intravenously every 3 or 6 weeks for 27 weeks. The other group undergoes observation without further pembrolizumab for the same period. Throughout the study, patients have tumor biopsies and blood collected, along with imaging such as mammography, breast ultrasound, or MRI during follow-up. Participants will be monitored for recurrence-free survival and overall survival for up to 10 years. The study also assesses adverse events, quality of life, financial impact, and work productivity at about 27 weeks after starting the assigned treatment or observation. Safety and treatment effects are tracked through biopsies, imaging, blood tests, and patient questionnaires during the study and follow-up.

Age: 18Years +All GendersPhase 3
846 locations
E

Actively Recruiting

Researchers are evaluating new software features designed for the Rhythmia Mapping System, a device used in catheter-based endocardial mapping for patients with atrial or ventricular tachyarrhythmias. The purpose is to study how these next-generation software updates perform during standard cardiac mapping and ablation procedures. This observational study collects data to help guide the development of improved software for future commercial releases. Participants undergo their usual catheter-based mapping and ablation treatments using the commercial Rhythmia Mapping System. During these standard procedures, raw cardiac signals are streamed from the commercial system to an investigational workstation running prototype software. These new software features are tested in parallel and do not affect the physicians clinical decisions or treatment. During the study, data are collected from the mapping procedures, and physician feedback on the softwares performance is gathered immediately after each procedure. The study involves no changes to the participants usual care. Researchers measure how well the new software performs without impacting patient safety or treatment outcomes. Participation time aligns with the standard care visit, and no additional follow-up related to the software testing is required.

Age: 18Years +All Genders
8 locations
S

Actively Recruiting

Researchers are investigating precursor hematological cancers, such as early myelodysplastic syndromes MDS, monoclonal gammopathy of undetermined significance MGUS, smoldering multiple myeloma, and other low-grade blood cancers. This study aims to understand the genetic and molecular changes that occur in these blood cancers and how they relate to disease progression and clinical outcomes. By analyzing these molecular alterations, scientists hope to improve prevention and treatment strategies for blood cancers. The study uses tissue samples already collected during participants clinical care, including blood, bone marrow, lymph nodes, urine, and other specimens. Additional samples may be collected for research purposes, such as a small blood sample or a gentle cheek swab to obtain normal cells for comparison. Researchers may create living cell lines from the tissue samples for future studies. Participant specimens and data may be stored securely and shared with research repositories to aid in further genetic research. Participants will not undergo extra clinical tests beyond their usual care but will be asked for permission to use their samples and clinical information. Follow-up visits will be conducted at regular intervals to monitor disease progression risk. The main outcome measured is identifying molecular changes in patients cells over a 10-year period. Throughout the study, privacy and confidentiality of participant information will be protected, and no additional risks beyond routine care are expected.

Age: 18Years +All Genders
7 locations
E

Actively Recruiting

Researchers are evaluating the addition of pembrolizumab, a type of immunotherapy, to standard chemotherapy for patients with stage IIA, IIB, IIIA, or IIIB non-small cell lung cancer NSCLC that has been completely removed by surgery. This phase III trial aims to compare disease-free survival and overall survival between different treatment approaches, including chemotherapy alone and chemotherapy combined with pembrolizumab. The study also investigates side effects, drug discontinuation rates, quality of life, and specific biomarkers such as PD-L1 expression and tumor mutational burden. Participants are randomly assigned to one of two treatment groups. Both groups initially receive one of four chemotherapy regimens every 21 days for four cycles, chosen by their doctor. In one group, pembrolizumab is given after chemotherapy as an intravenous infusion every 21 days for up to 17 cycles or every 6 weeks for up to 16 cycles. In the other group, pembrolizumab is given together with chemotherapy during the initial cycles and then continued as monotherapy. Patients undergo various scans and blood tests throughout the study, including echocardiograms, MRIs, CT scans, and blood sample collections. During the trial, participants are closely monitored for disease status and side effects. Follow-up visits occur six weeks after treatment, then every three months for two years, every six months for years two to four, and annually for up to ten years after randomization. Quality of life questionnaires and symptom assessments are also completed. The main measure of success is disease-free survival, tracked for up to five years after enrollment. Safety and overall survival are reviewed for up to ten years to ensure long-term monitoring.

Age: 18Years +All GendersPhase 3
1151 locations
S

Actively Recruiting

Researchers are evaluating dosing strategies of CDK46 inhibitors in patients aged 60 and older with hormone receptor positive, HER2 negative metastatic breast cancer. The study compares the standard full-dose approach with a titrated dosing method that starts at a lower dose and increases as tolerated. The goal is to help more older patients tolerate side effects and stay on treatment longer to gain the most benefit from these drugs. Participants will choose either palbociclib or ribociclib combined with endocrine therapy, including aromatase inhibitors or fulvestrant. They will be randomly assigned to either the indicated dosing arm, starting at the full approved dose, or the titrated dosing arm, starting at a lower dose and escalating if well tolerated. The treatment cycles follow a 28-day schedule, with doses given orally on days 1-21. During the study, participants will be monitored for time to treatment discontinuation, toxicities, quality of life, dose adjustments, and healthcare utilization for up to 48 months. Patient-reported outcomes will be collected to understand tolerance better. Telehealth visits and remote consenting are allowed per institutional guidelines, supporting patient convenience throughout the trial.

Age: 60Years +All GendersPhase 3
92 locations